Characterization of the novel HLA-B*57:169 allele by next generation sequencing.

HLA-B*57:169 differs from HLA-B*57:01:01:12 by one nucleotide substitution at position 2512, codon 320 located in exon 6.

Characterization of the novel HLA-DPB1*04:02:01:40 allele by Oxford nanopore sequencing (ONT) technology.

Full-length sequence of HLA-DPB1*04:02:01:40 covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Full genomic sequence of the HLA-DRB3*03:46 allele identified by third generation sequencing.

Full-length sequence of HLA-DRB3*03:46 covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Full genomic sequence of the HLA-DPA1*01:115 allele identified by next generation sequencing.

Full-length sequence of HLA-DPA1*01:115 covers the 5'-untranslated region (UTR), all introns and exons and the 3'-UTR.

Characterization of the novel HLA-DPA1*02:03:05 allele by next generation sequencing.

HLA-DPA1*02:03:05 differs from HLA-DPA*02:03:04 by three nucleotide substitution located in exon 3.

Characterization of the novel HLA-A*32:172 allele by next generation sequencing.

HLA-A*32:172 differs from HLA-A*32:01:01:01 by one nucleotide substitution at position 1013, codon 314 located in exon 6.

Full-length genomic sequence of HLA-DQA1*02:19 by next generation sequencing.

Full-length sequence of HLA-DQA1*02:19 covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Invega Hafyera (Paliperidone Palmitate): Extended-Release Injectable Suspension for Patients With Schizophrenia.

The objective of this study was to describe the safety, efficacy, and potential role in therapy of once in 6 months paliperidone palmitate formulation (PP6M; Invega Hafyera). PP6M is a long-acting injectable antipsychotic recently approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia. A PubMed literature search was conducted using the following terms: paliperidone palmitate and long-acting antipsychotic injections (January 1, 2017, to November 1, 2022).

Characterization of the novel HLA-DPA1*01:144 allele by next generation sequencing.

HLA-DPA1*01:144 differs from HLA-DPA*01:03:01:04 by one nucleotide substitution at position 44, codon-17 located in exon 1.

Characterization of the novel HLA-C*05:01:72 allele by next generation sequencing.

Full-length sequence of HLA-C*05:01:72 covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Full genomic sequence of the HLA-DRB3*02:32 allele by Single Molecule Real-time Sequencing Technology.

Full-length sequence covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Characterization of the novel HLA-DPA1*02:72 allele by next generation sequencing.

HLA-DPA1*02:72 differs from HLA-DPA1*02:02:02:01 by one nucleotide substitution at position 4273, codon 86 located in exon 3.

Full genomic sequence of the HLA-DRB3*02:22:01 allele by single molecule real-time sequencing technology.

Full-length sequence covers the 5'-untranslated region (UTR), all introns and exons, and the 3' UTR.

Full genomic sequence of the HLA-DPA1*02:46 allele identified by next generation sequencing.

Full-length sequence of HLA-DPA1*02:46 covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Full genomic sequence of the HLA-C*07:308 allele identified by next generation sequencing.

Full-length sequence of HLA-C*07:308 covers the 5'-untranslated region (UTR), all introns and exons and the 3' UTR.

Full genomic sequence of the HLA-C*15:02:03 allele identified by next generation sequencing.

Full-length sequence of HLA-C*15:02:03 covers all introns and exons and the 3' UTR.

A novel allele, HLA-DPA1*01:87Q identified by next generation sequencing.

A point mutation in Exon 1, 1-3 (ATG>ACG) causes a non-synonymous change to the start codon, which may affect expression.

Participants' perceptions of a residency teaching certificate program: the quality, impact and benefits.

Background: Currently, there are no accreditation requirements for pharmacy resident teaching certificate programs (RTCPs) but rather suggested guidelines and documents for individual programs to follow. RTCP curriculums are often "handed-down" from past personnel and vary based on individual interpretation. Quality improvement may be overlooked when programs do not report to governing bodies.

Training upcoming academicians through interviews of pharmacy resident teaching certificate leaders.

Background: Discovering methods of Residency Teaching Certificate Programs (RTCPs) will allow for collaboration in developing best practices to ensure both high quality of programming and outcomes for participants.

Objective: The primary objective of this project is to describe and compare how RTCPs are conducted in the state of Ohio. Secondarily, to identify current practices in assessing RTCPs in both programmatic effectiveness and individual resident teaching outcomes.

Identifying and evaluating gaps in knowledge, skills, and qualities necessary for a career in academia.

Introduction: Due to demands for qualified faculty and educators, more pharmacy residency programs have adopted resident teaching certificate programs (RTCP). There is a lack of standardization and published research on what should be included in these programs. The primary objective of this study was to utilize an online survey to identify and evaluate perceived gaps in skills, qualities, and knowledge needed for a successful career in academia.

CE: Original Research: Identifying Hospitalized Patients at Risk for Harm: A Comparison of Nurse Perceptions vs. Electronic Risk Assessment Tool Scores.

Unlabelled: : Objective: In many hospitals, nurse-led "safety huddles" are used to relay patient safety information, although whether this effectively identifies patients at risk for harm has not been determined. New electronic risk assessment tools are designed to identify patients at risk for harm during hospitalization, based on specific markers in the electronic health record. This study sought to compare the results of both methods.

Repeat infection with gonorrhoea in Sheffield, UK: predictable and preventable?

Background: Repeat infection with gonorrhoea may contribute significantly to infection persistence and health service workload. The authors investigated whether repeat infection is associated with particular subgroups who may benefit from tailored interventions.

Methods: Data on gonorrhoea diagnoses between 2004 and 2008 were obtained from Sheffield sexually transmitted infection clinic.

Genital warts and cost of care in England.

Objectives: To estimate the total number of cases of, and cost of care for, genital warts (GWs) in England, to inform economic evaluations of human papillomavirus vaccination.

Methods: The number of GW cases seen in general practices (GPs) and in genitourinary medicine (GUM) clinics was estimated using the General Practice Research Database and the GUM Clinic Activity Dataset. The overlap in care of cases in the two settings was estimated.

Polymorphism and regulation of the spxB (pyruvate oxidase) virulence factor gene by a CBS-HotDog domain protein (SpxR) in serotype 2 Streptococcus pneumoniae.

spxB-encoded pyruvate oxidase is a major virulence factor of Streptococcus pneumoniae. During aerobic growth, SpxB synthesizes H2O2 and acetyl phosphate, which play roles in metabolism, signalling, and oxidative stress. We report here the first cis- and trans-acting regulatory elements for spxB transcription.